# GLP-1 side effects: common, uncommon, and when to ask for help

> What the trials actually show about GLP-1 side effects — which are common and self-limiting, which are rare but serious, and the symptoms that mean call now.

**Evidence grade:** Established (rung 1 of 8 on the Peptide Evidence Ladder) · **Last reviewed:** 2026-06-30 · **Source page:** https://thepeptideera.com/evidence/glp1-side-effects

## Short answer
Across large trials, the most common GLP-1 side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — usually mild-to-moderate, dose-related, and easing with time. Serious problems such as pancreatitis, gallbladder disease, and bowel obstruction are uncommon but real and well-documented on the labels. Most early discomfort is expected; specific red-flag symptoms are not, and warrant prompt clinical contact.

## Safety essentials worth knowing

These apply to GLP-1 and dual/triple-agonist medicines generally. They’re label-level points, not the full list, and not advice about you — your prescriber and the FDA label are the authority.

- **Pregnancy & breastfeeding:** these medicines are not recommended in pregnancy, and intentional weight loss is generally not advised in pregnancy; the labels advise stopping before a planned pregnancy. Breastfeeding status is a conversation to have with your clinician.
- **Birth control:** some of these medicines (such as tirzepatide) can make *oral* contraception less reliable. If you could become pregnant, ask about backup or non-oral contraception.
- **Thyroid boxed warning:** this drug class carries an FDA boxed warning (thyroid C-cell tumours seen in rodents) and is not for people with a personal or family history of medullary thyroid cancer (MTC) or MEN 2.
- **Blood sugar:** combined with insulin or a sulfonylurea, these medicines can cause low blood sugar — those other medicines often need prescriber-managed adjustment, not self-adjustment.
- **Eating disorders:** an appetite-suppressing medicine warrants particular caution with a current or past eating disorder; disclose this to your clinician.
- **Surgery, sedation & endoscopy:** because these medicines slow stomach emptying, tell your surgical or anaesthesia team you take a GLP-1 well in advance — they'll decide with you whether to continue or hold it (more: https://thepeptideera.com/evidence/glp1-and-surgery).

Most people starting a GLP-1 medicine want the same two things: a realistic picture of what the first weeks will feel like, and a clear line between "this is normal" and "this needs a clinician." The trials answer the first question well. The second question is where calm, specific knowledge matters most — because the rare problems are the ones worth recognising early.

This page distils what the medicines' own large trials and labels report. It describes; it does not prescribe. It contains no doses, and it is not a substitute for the person who knows your history.

**One caveat before the symptoms: pregnancy.** These medicines are **not recommended in pregnancy or while breastfeeding**, and some (such as tirzepatide) can make **oral contraception less reliable**. If you could become pregnant, contraception and any plan to conceive are a conversation to have with your prescriber *before* starting — not after.

## What strong evidence says

The dominant side effects of GLP-1 and dual/triple-agonist medicines are **gastrointestinal**, and this sits on the top rung of the Evidence Ladder: consistent findings across several large randomised trials of approved drugs used for their approved purpose.

In STEP 1, the semaglutide trial in obesity, gastrointestinal events — most often nausea, diarrhea, vomiting, and constipation — were the most frequently reported events, occurring in about three-quarters of people on the drug versus roughly half on placebo. Crucially, they were **typically mild-to-moderate, transient, and tended to subside over time.** The same pattern repeats with tirzepatide in SURMOUNT-1 and with semaglutide in the very large SELECT cardiovascular trial, where the GI profile was the main driver of side-effect-related discontinuation but most participants continued treatment.

Three things are well-established about these common effects:

- **They cluster around dose increases.** Symptoms tend to appear or worsen when the dose steps up, which is part of why [titration schedules exist](/evidence/glp1-dosing-and-titration/) — they are a side-effect-management tool, not an arbitrary delay.
- **They usually settle.** For most people the nausea curve bends down with time rather than up.
- **They are manageable for most, but not all.** A minority stop because of GI symptoms; in STEP 1 that was a small single-digit percentage, higher than placebo but far from universal.

Beyond the common GI effects, the labels also document **uncommon-but-serious** events as a class signal: **acute pancreatitis**, **acute gallbladder disease** (gallstones and inflammation, partly linked to rapid weight loss), and gastrointestinal effects severe enough to matter — **ileus, intestinal obstruction, and severe constipation with fecal impaction.** These are not common, but they are real, documented, and the reason a few symptoms deserve a low threshold for seeking care. The Wegovy label also carries a boxed warning about [thyroid C-cell tumours](/articles/glp1-and-cancer-risk) seen in rodents, with the drug contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.

## What weaker evidence suggests

Not everything discussed around GLP-1s is equally settled.

**Loss of lean mass** during rapid weight loss is frequently raised. It is true that a portion of weight lost is lean tissue: dedicated body-composition substudies of these trials, using DXA scans, do report that some of the loss is lean mass alongside the larger fat-mass reduction (the STEP 1 analysis for semaglutide and the SURMOUNT-1 DXA substudy for tirzepatide). But the leap from "lean mass on a scan" to a proven decline in real-world strength, falls, or fractures is **emerging and unproven**, not established. The scan number is not the same as a functional outcome, and the long-term clinical significance is still being worked out.

The **ileus and obstruction** signal deserves an honest grade too: it appears on labels and in pharmacovigilance reporting, but much of the supporting real-world data is **observational**, which can show association without proving the rate or the cause. That is enough reason to take the symptom seriously — not enough to state a precise risk.

Finally, the **investigational** triple agonist **retatrutide** produced large weight loss in a phase 2 trial, with a side-effect profile dominated by the same dose-related, mostly mild-to-moderate GI events. Retatrutide is **not FDA-approved** and remains under study; its longer-term safety is genuinely not yet known.

For the rarer and newer signals people ask about most — the eye condition **NAION**, gallbladder problems, mood, and reproductive and cycle changes — we grade each one on its own evidence on a dedicated page: [GLP-1's lesser-known side effects](/evidence/glp1-lesser-known-side-effects).

## What is unknown

- **Who will struggle and who won't.** Trials report averages. There is no reliable way yet to predict in advance who will have severe nausea, who will tolerate the medicine easily, or who is a slow versus fast responder in the early weeks.
- **The true rate of the rare events** outside trial conditions — especially with unsupervised or non-prescription use, where adverse events go largely unreported and no real safety database exists.
- **Long-term effects of the newest agents**, where follow-up is still short and the investigational molecules have no multi-year human safety record.

When you see a confident number attached to any of these, treat the confidence as a red flag rather than reassurance.

## Questions to ask a clinician

- What is the plan if nausea becomes severe — do I wait, adjust, or call?
- Which symptoms should prompt me to contact you immediately, and how do I reach you (and what do I do) if I can't?
- How will we protect muscle and nutrition while I'm losing weight — what should I be eating and doing?
- Given my history, am I at any particular risk for gallbladder problems or pancreatitis?
- If I could become pregnant: what contraception do you recommend, and how long before trying to conceive should I stop?
- How will we monitor progress, and what would make us pause or change course?

## Red flags / when to seek care

Common early discomfort is one thing. The following are not "ride-it-out" symptoms — they are reasons to contact a clinician promptly, and for the severe versions, to seek urgent care or your local emergency number:

- **Severe or persistent abdominal pain**, especially pain that is intense, radiates to the back, or comes with repeated vomiting — a possible sign of **pancreatitis**, which needs evaluation, not waiting.
- **Pain in the upper-right abdomen, fever, or yellowing of the skin or eyes** — possible **gallbladder disease.**
- **A bloated, distended belly with vomiting and no bowel movements** — possible **bowel obstruction or ileus.**
- **Signs of dehydration** from prolonged vomiting or diarrhea — dizziness, very dark or scant urine, confusion.
- **Inability to keep fluids down** for an extended period.

If something feels genuinely wrong in your body, that is not a claim to grade on a ladder — it is a reason to call. The titration phase asks for patience with the ordinary discomforts; it does not ask you to ignore the symptoms above.

## Sources (7)
1. Wilding et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1, NEJM 2021) — https://pubmed.ncbi.nlm.nih.gov/33567185/ [RCT]
2. Jastreboff et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, NEJM 2022) — https://pubmed.ncbi.nlm.nih.gov/35658024/ [RCT]
3. Lincoff et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT, NEJM 2023) — https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 [RCT]
4. Jastreboff et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (NEJM 2023) — https://pubmed.ncbi.nlm.nih.gov/37366315/ [RCT]
5. WEGOVY (semaglutide) injection — FDA Prescribing Information — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b [LABEL]
6. STEP 1 body-composition analysis — semaglutide effects on lean and fat mass (DXA substudy) — https://pmc.ncbi.nlm.nih.gov/articles/PMC8089287/ [RCT]
7. Look et al. SURMOUNT-1 DXA body-composition substudy — tirzepatide effects on lean and fat mass (Diabetes Obes Metab 2025) — https://pmc.ncbi.nlm.nih.gov/articles/PMC11965027/ [RCT]

---
From The Peptide Era (https://thepeptideera.com) — evidence-graded, primary-sourced answers about GLP-1 medicines. Education, not medical advice. No doses, no sourcing.